Lipocine Reports Data From Its qEEG Study Of Its Oral Brexanolone, A Proprietary Bioidentical NAS Being Developed For The Treatment Of Post-partum Depression - Filing
Benzinga Newsdesk 2 years ago
News
The results indicate robust central nervous system (CNS) activity of oral brexanolone, with concentration- and time-dependent post-dose changes in qEEG. These results confirm GABAA positive allosteric modulation and
The results indicate robust central nervous system (CNS) activity of oral brexanolone, with concentration- and time-dependent post-dose changes in qEEG. These results confirm GABAA positive allosteric modulation and support future development of oral brexanolone in neuropsychiatric indications.
"“We are pleased with the qEEG results that confirm target engagement of oral bioidentical brexanolone, which suggests potential utility in treating numerous psychiatry indications, including depression and anxiety, and neurology indications such as essential tremor and epilepsy,” said Dr. Mahesh Patel, President and CEO of Lipocine Inc.
"These positive biomarker results and favorable safety profile support further development of oral brexanolone."